Table 2.

HRs and 95% CIs for prostate cancer recurrence and death by ERG status among 1,180 men treated with radical prostatectomy for prostate cancer, Physicians' Health Study, and Health Professionals Follow-Up Study cohorts 1983–2011

Model 1aModel 2b
CharacteristicHR (95% CI)HR (95% CI)
Lethal prostate cancer (no. events: 85)c
 ERG negative1.001.00
 ERG positive0.93 (0.61–1.43)0.85 (0.55–1.31)
Biochemical recurrence (no. events: 266)
 ERG negative1.001.00
 ERG positive0.99 (0.78–1.26)0.89 (0.70–1.13)
All-cause mortality (no. events: 311)d
 ERG negative1.001.00
 ERG positive0.84 (0.67–1.05)0.84 (0.67–1.05)
  • aAdjusted for age at diagnosis (<60, 60–64, 65–69, 70+), and cohort (Physicians' Health Study, Health Professionals Follow-Up Study).

  • bAdjusted for age at diagnosis (<60, 60–64, 65–69, 70+), cohort (Physicians' Health Study, Health Professionals Follow-Up Study), tumor stage (T2, T3, T4/N1/M1), and Gleason score (≤6, 3+4, 4+3, ≥8).

  • cLethal prostate cancer includes metastases to distant organs or bone, and prostate cancer death.

  • dAll-cause mortality includes prostate cancer death and death due to any other cause.